AlphAIalphai — Financial news for AI agents
financialcontent.comSEP 12 min read$MYGN

Why Myriad Genetics (MYGN) Stock Is Down Today

Myriad Genetics (MYGN) shares fell 6.2% after Piper Sandler downgraded the stock to Underweight, citing the need for major strategic action. The stock later recovered slightly to $3.10, down 3.9% from the previous close. MYGN is down 49.6% YTD and 62.2% below its 52-week high.

Original reporting
financialcontent.com
Published Sep 1, 2026, 7:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Why Myriad Genetics (MYGN) Stock Is Down Today — source image
Source · financialcontent.com
Decision brief

The 30-second read

$MYGNBearishMed
01

Why it matters

The downgrade caused a 6.2% price drop, indicating immediate market reaction.

02

Market read

The downgrade and price move present a short‑term trading opportunity and signal potential longer‑term challenges.

03

What to watch

Recent cash burn reduction and pipeline progress are not reflected in the downgrade.

Relevance 7/10Novelty 7/10Timing: afternoon today

Background

Piper Sandler analyst Dave Westenberg issued a two‑notch downgrade, citing the need for major strategic action.

Company-level read

Ticker impact

$MYGNBearishHigh confidence
Context

Shares fell 6.2% in the afternoon after Piper Sandler double‑downgraded Myriad Genetics to Underweight.

Expected impact

Further downside risk if no strategic action is announced.

Evidence & confidence

Analyst downgrade is a fresh, material catalyst; price already reacted strongly.

Market effects

Sector

Biotech sector may see heightened scrutiny of peers after a downgrade.

Regional

U.S. biotech stocks could face broader pressure in the same session.

Global

Limited to U.S. listed genetics companies.

Counterpoint

What could challenge this read

The downgrade may be overly pessimistic if the company announces a strategic partnership soon.

Key entities

  • company
    Myriad Genetics

    Genetic testing firm (NASDAQ: MYGN).

  • analyst_firm
    Piper Sandler

    Investment bank that issued the downgrade.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 1
$MYGNMed

Why is Myriad Genetics stock tumbling today?

Myriad Genetics (MYGN) shares fell 7.1% premarket after Piper Sandler downgraded the stock to Underweight, cutting its price target to $2.00 from $5.45. The firm cited concerns over the company's profitability and weak Q2 2026 results, including a 10.5% year-over-year revenue decline. The broader market also declined, with the NASDAQ down 0.9%.

investing.com2 min
AUG 1
$MYGNMedAI 8/10

Myriad Genetics Q2 Earnings Call Highlights

Myriad Genetics (MYGN) suspended adjusted EBITDA guidance due to uncertainty around initiatives. In Q2 it reported an adjusted EBITDA loss of $16.9M and adjusted loss per share of $0.25. Gross margin fell to 66.6% (66.6% excluding an $11M estimate impact: 68.4%). Liquidity was about $190M. Management cited worsening payer reimbursement friction and launched revenue-cycle and efficiency initiatives.

finance.yahoo.com6 min
JUL 31
$MYGNHighAI 9/10

Why Myriad Genetics (MYGN) Shares Are Falling Today

Myriad Genetics (MYGN) shares fell 46.1% after the company reported Q2 2026 results that missed Wall Street expectations and cut its full-year forecast. Revenue was $190.7 million, down 10.5% year over year, with an adjusted loss per share of $0.25. Full-year revenue guidance was reduced to a $780 million midpoint.

financialcontent.com4 min
JUL 30
$MYGNHighAI 9/10

Myriad Genetics (NASDAQ:MYGN) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 28.6%

Genetic testing company Myriad Genetics (NASDAQ: MYGN) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 10.5% year on year to $190.7 million. The company’s full-year revenue guidance of $780 million at the midpoint came in 9.7% below analysts’ estimates. Its non-GAAP loss of $0.25 per share was significantly below analysts’ consensus estimates. Is now the time to buy Myriad Genetics? Find out by accessing our full research report, it’s free.

financialcontent.com4 min